07:00 Mon 14 Dec 2020
Physiomics PLC - Approval of NIHR-funded PARTNER study
Physiomics plc
("Physiomics" or "the Company")
Physiomics announces approval of NIHR-funded PARTNER study
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that its National Institute for Health Research ("NIHR") Invention for Innovation ("i4i") programme funded observational clinical study (designated "PARTNER"), has this week received both ethics committee and Health Research Authority (HRA) approval and it is now expected that the study will commence early in 2021.
The PARTNER study is being funded by the UK Department of Health & Social Care, which will provide 100% reimbursement of project costs of up to
The PARTNER study, originally expected to run over a 12-month period from
Dr
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
+44 (0)20 7409 3494
Hybridan LLP (Broker)
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
About The National Institute for Health Research (NIHR)
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE